Self-Assembled HA-Peptide Nanoparticles for Ocular Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for ocular angiogenesis-related diseases, such as age-related macular degeneration and corneal neovascularization, suffer from side effects like weight gain, hypertension, and infection risks, and require frequent injections that can cause complications.
Innovation Solution
A self-assembled nanoparticle composed of hyaluronic acid and a therapeutic peptide, such as the Nox2-targeted inhibitory gp91 ds-tat peptide, is developed to inhibit angiogenesis by encapsulating up to 99% of the peptide, allowing for targeted delivery to anterior or posterior eye segments, enhancing drug retention and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral steroids are used to treat ocular diseases, then anti-inflammatory effect is improved, but side effects such as weight gain, hypertension, and infection risks increase
Solution Approach 1:
The patent segments the therapeutic approach by using nanoparticle carriers to deliver anti-inflammatory agents directly to ocular tissues, separating the therapeutic effect from systemic circulation and thereby reducing systemic side effects while maintaining local efficacy
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that transports anti-inflammatory drugs to the target site, enabling controlled delivery and reducing direct systemic exposure to steroids, thus minimizing side effects like weight gain and hypertension
2Reliability
If frequent intravitreal injections are administered, then therapeutic effect is improved, but complications such as endophthalmitis, hemorrhages, and inflammation increase
Solution Approach 1:
The patent employs nanoparticle formulations that are pre-designed with sustained release capabilities, allowing a single injection to provide prolonged therapeutic effect and eliminating the need for frequent repeat injections, thereby reducing cumulative injection-related complications
Solution Approach 2:
The nanoparticle delivery system provides continuous release of therapeutic agents at the injection site, maintaining effective drug concentrations over extended periods and replacing the need for repeated discrete injection events that cause cumulative trauma and infection risk
3Quantity of substance
If high encapsulation efficiency is achieved, then drug retention is improved, but nanoparticle stability may be compromised
Solution Approach 1:
The patent optimizes nanoparticle parameters such as size, surface charge, and material composition to achieve the optimal balance between high drug encapsulation efficiency and colloidal stability, ensuring both high drug retention and resistance to aggregation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle effectively inhibits new blood vessel formation in the eye, providing prolonged drug retention and minimizing adverse reactions, thus offering a safer and more effective treatment for ocular angiogenesis.
Implementation Method 1
self-assembled nanoscale particle comprising hyaluronic acid (HA) and a therapeutic peptide
Data Source
AI summary
Provided is a nanoparticle or a pharmaceutical composition including the same for treating or remitting a neovascularization or an angiogenesis in eye segments, and the nanoparticle includes a hyaluronic acid and a therapeutic peptide. Also provided is a method for inhibiting formation or growth of blood vessels by administration of the nanoparticle or the pharmaceutical composition of the present disclosure to a subject in need thereof.